MMV ups funding under deal with Anacor to allow Phase I trial of malaria candidate
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals and Medicines for Malaria Venture (MMV) have extended their existing agreement over the clinical development of AN3661, a boron-based drug candidate for malaria. Under the extended deal, MMV will now provide additional funding to allow completion of the Phase I clinical trials and a human proof-of-concept study for the compound.